Guideline Panel Meeting: Testicular Cancer (2018)

November 13, 2018 to November 14, 2018

The purpose is to provide clinicians with evidence and consensus-based principles and strategies for the diagnosis and management of testicular cancer based on the current state of both clinical practice and the medical literature. There currently exists gaps in knowledge about how to best to diagnose and manage such a condition. There exists inconsistency in practice patterns, which provides an area for improvement of patient care. 

Target Audience

This course is designed for:

  • Urologists

Learning Objectives

After particpating in this activity, participants will be able to: 

  • Expand and update urology knowledge base
  • Analyze clinical skills and patient care methods towards improving their quality
  • Identify methods to improve teaching skills from familiarity with the most recent information and its clinical application
  • Demonstrate written communication skills from exposure to peer review of written materials
  • Implement improved critical thinking skills


Course summary
Available credit: 
  • 11.00 AMA PRA Category 1 Credit™
  • 11.00 Non-Physician Participation
Course opens: 
Course expires: 
Event starts: 
11/13/2018 - 7:30am EST
Event ends: 
11/14/2018 - 12:30pm EST

Day 1: November 13, 2018

7:30am            Breakfast

8:00am            Welcome & Introductions                                                            Abid Khan

8:10am            Conflict of Interest Disclosures and Panel Responsibilities    Brooke Bixler


8:30am            Guidelines Stages Overview                                                         Brooke Bixler

8:45am            Categorizing Guidelines Statements                                           Brooke Bixler

9:00am            Evidence Report Overview                                                           Dr. Eric Bass               

10:00am          Evidence Report Discussion/Statement Development           Panel

                        Key Question 1—Drs. Pierorazio and Sheinfeld

                        Key Question 2—Drs. Eggener and Karam

                        Key Question 3—Drs. Feldman and Daneshmand

                        Key Question 4—Drs. Pierorazio and Masterson

                        Key Question 5a (Seminoma…)—Drs. Liauw and Daneshmand

                        Key Question 5a (NSGCT…)—Drs. Sheinfeld and Gilligan

                        Key Question 5b—Drs. Meeks and Leibovich

                        Key Question 5c—Drs. Eggener and Leibovich

                        Key Question 6a—Drs. Masterson and Liauw

                        Key Question 6b—Drs. Karam and Feldman

                        Key Question 7—Drs. Gilligan and Meeks, Mr. Chelnick

10:30am          Break (10 min)                                               

12:30pm          Lunch

1:00pm            Guideline Statement Development                                          Panel

2:45pm            Break (10 min)

4:30pm            Recap and Day 2 Agenda                                                            Brooke Bixler

4:45pm            Shuttle Departs AUA to hotel                                                 

6:00pm            Shuttle departs from hotel to dinner

Day 2: November 14, 2018

8:00am            Breakfast

8:30am            Drafting Guideline Statements CONT’D                                    Panel

10:30am          Break (10 min)

11:30am          Discussion of Diagnostic/ Treatment Algorithm                      Panel

12:15pm          Next Steps                                                                                      Brooke Bixler

12:30pm          Meeting Adjourned

AUA Headquarters
Linthicum, MD 21090
United States

Faculty & Planner Disclosures






Andrew Stephenson, MD

Guideline Panel Chair

Genomic Health

 Consultant or Advisor, Meeting Participant or Lecturer






Consultant or Advisor


Victor Nitti, MD

Chair, Office of Education


Health Publishing, Scientific Study or Trial





Health Publishing, Scientific Study or Trial




Serenity Pharmeuticals

Investment Interest





Scientific Study or Trial


Michael Abern, MD

Chair, COI Review Work Group


Dept. of Defense Prostate Cancer Research Program

Scientific study or Trial, Consultant or Advisor




American Urological Association Office of Edu

Consultant or Advisor


Brooke Bixler

AUA Staff

Nothing to disclose




Panel Member Disclosures

PDF iconTesticular Cancer Panel COI.pdf

Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The American Urological Association designates this live activity for a maximum of 11.0  AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 CreditTM.

Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Resolution of Identified Conflict of Interest: All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Conflict of Interest Review Work Group or its subgroup.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty

Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.



Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Consent to Use of Photographic Images: Attendance at or participation in AUA meetings and other activities constitutes an agreement by the registrant to AUA's use and distribution (both now and in the future) of the attendee's image or voice in photographs and electronic reproductions of such meetings and activities.

Audio, Video and Photographic Equipment: The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meeting rooms.

Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

Special Assistance/Dietary Needs: The AUA complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, please see the registration desk.

Available Credit

  • 11.00 AMA PRA Category 1 Credit™
  • 11.00 Non-Physician Participation
Please login or register to take this course.

This activity is restricted to members of the Testicular Cancer Guideline Panel.